Indoprofen bei juveniler chronischer Polyarthritis

24 patients with juvenile rheumatoid arthritis, aged 3 to 15 years, were treated with the propionic add derivative Indoprofen for 12 weeks in an open, non-comparative study. The daily dose was 10 to 20 mg/kg body weight. Assessment parameters both before therapy and after 1, 4, 8, 12 weeks were clinical parameters, laboratory examinations and the corticosteroid dose. Compatibility of preparation was also a factor employed in assessment. Indoprofen produced a pronounced and statistically significant analgesic action and a good-inflammatory effect. Improvement was noted in 58% of the patients after a 12-week course.

In 3 children, treatment was discountinued due to macrohämaturia, whereas discontinuation became necessary in 2 patients because of exacerbation of the disease.